CANDESARTAN POLPHARMA tablett Estonia - Tiếng Estonia - Ravimiamet

candesartan polpharma tablett

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 8mg 28tk; 8mg 14tk; 8mg 56tk

CANDESARTAN POLPHARMA tablett Estonia - Tiếng Estonia - Ravimiamet

candesartan polpharma tablett

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 4mg 14tk; 4mg 28tk

CANDESARTAN POLPHARMA tablett Estonia - Tiếng Estonia - Ravimiamet

candesartan polpharma tablett

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 32mg 56tk; 32mg 14tk

CANDESARTAN POLPHARMA tablett Estonia - Tiếng Estonia - Ravimiamet

candesartan polpharma tablett

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 16mg 28tk; 16mg 14tk

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Bremamectin süstelahus Estonia - Tiếng Estonia - Ravimiamet

bremamectin süstelahus

bremer pharma gmbh - ivermektiin - süstelahus - 10mg 1ml 250ml 1tk; 10mg 1ml 100ml 1tk

Pirfenidone axunio (previously Pirfenidone AET) Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

pirfenidone axunio (previously pirfenidone aet)

axunio pharma gmbh - pirfenidone - idiopaatiline kopsufibroos - immunosupressandid - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Prialt Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

prialt

esteve pharmaceuticals gmbh - zikonotiid - injections, spinal; pain - valuvaigistid - zikonotiid on näidustatud raske, kroonilise valu raviks patsientidel, kes vajavad intratekaalset (it) analgeesiat.

ERLOTINIB TEVA PHARMA õhukese polümeerikattega tablett Estonia - Tiếng Estonia - Ravimiamet

erlotinib teva pharma õhukese polümeerikattega tablett

teva pharma b.v. - erlotiniib - õhukese polümeerikattega tablett - 150mg 1tk 30tk

GLICLAZIDE POLPHARMA toimeainet modifitseeritult vabastav tablett Estonia - Tiếng Estonia - Ravimiamet

gliclazide polpharma toimeainet modifitseeritult vabastav tablett

pharmaceutical works polpharma s.a. - gliklasiid - toimeainet modifitseeritult vabastav tablett - 30mg 56tk; 30mg 98tk; 30mg 30tk; 30mg 10tk; 30mg 90tk; 30mg 100tk; 30mg 60tk; 30mg 20tk; 30mg 28tk; 30mg 120tk